TheraRadar

Medytox

Pre-Approval PRO BETA

Also known as: Medy-Tox, Medytox Korea

đź”´

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 2/7/2022

42
Total Trials
23
Phase 3
8
Phase 2
0
Recruiting
430
Score

Pipeline by Phase

Phase 3
23
Phase 2
8
Phase 1
7

Therapeutic Focus

Glabellar Frown Lines Glabellar Lines Lateral Canthal Lines Muscle Spasticity Submental Fat

Clinical Trials (42)

NCT04157686 Phase 3 COMPLETED

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

Started: 10/23/2019

NCT03785145 Phase 3 COMPLETED

MT10109L in the Treatment of Lateral Canthal Lines

Started: 12/20/2018

NCT03795922 Phase 3 COMPLETED

MT10109L in the Treatment of Glabellar Lines

Started: 12/24/2018

NCT03732833 Phase 3 COMPLETED

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

Started: 11/5/2018

NCT03721016 Phase 3 COMPLETED

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

Started: 10/26/2018

NCT05195112 Phase 3 COMPLETED

Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

Started: 12/24/2021

NCT03289702 Phase 3 COMPLETED

CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)

Started: 11/13/2017

NCT03837561 Phase 3 COMPLETED

The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines

Started: 12/13/2018

NCT03760198 Phase 3 COMPLETED

Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis

Started: 8/3/2018

NCT03452345 Phase 3 COMPLETED

MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy

Started: 4/9/2018

NCT03908008 Phase 3 COMPLETED

Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line

Started: 1/1/2014

NCT03905304 Phase 3 COMPLETED

Efficacy and Safety of MEDITOXIN® in Cervical Dystonia

Started: 1/9/2013

NCT01585220 Phase 3 COMPLETED

Efficacy and Safety Study of Neuramis in Correction of Nasolabial Fold

Started: 2/9/2012

NCT01313767 Phase 3 COMPLETED

MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity

Started: 3/1/2011

NCT01237977 Phase 3 COMPLETED

Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines

Started: 11/23/2009

NCT03317574 Phase 3 COMPLETED

MEDITOXIN® in Treatment of Crow's Feet Line

Started: 8/17/2017

NCT03232320 Phase 3 COMPLETED

Meditoxin® Treatment in Patients With Cervical Dystonia

Started: 7/6/2017

NCT03216408 Phase 3 COMPLETED

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines

Started: 3/30/2016

NCT03216473 Phase 3 COMPLETED

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm

Started: 5/25/2016

NCT02751034 Phase 3 COMPLETED

Efficacy and Safety Evaluation Study of Neuramis® Deep Lidocaine in Correction of Nasolabial Fold

Started: 6/1/2013

NCT05321979 Phase 3 COMPLETED

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Started: 2/7/2022

NCT05059587 Phase 3 COMPLETED

Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines

Started: 8/30/2021

NCT01485601 Phase 2 COMPLETED

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines

Started: 12/7/2011

NCT04143815 Phase 2 COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines

Started: 5/20/2019

NCT04143854 Phase 2 COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Lateral Canthal Lines

Started: 5/21/2019

NCT04144049 Phase 2 COMPLETED

A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

Started: 9/10/2019

NCT03894748 Phase 2 COMPLETED

Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)

Started: 12/1/2011

NCT02292472 Phase 2 COMPLETED

Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy

Started: 10/6/2014

NCT01588574 Phase 2 COMPLETED

Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia

Started: 8/1/2012

NCT05217355 Phase 2 COMPLETED

A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Started: 12/28/2021

NCT05164003 Phase 1 COMPLETED

CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase1)

Started: 7/17/2017

NCT03796351 Phase 1 COMPLETED

Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®

Started: 9/1/2012

NCT03905291 Phase 1 COMPLETED

Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects

Started: 7/31/2018

NCT03317717 Phase 1 COMPLETED

Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male Volunteers

Started: 10/12/2017

NCT03371342 Phase 1 COMPLETED

Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder

Started: 12/13/2017

NCT03547141 Phase 1 COMPLETED

Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers

Started: 4/16/2018

NCT03647982 Phase 1 COMPLETED

Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers

Started: 3/20/2018

NCT03289169 Phase 4 COMPLETED

Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines

Started: 12/30/2016

NCT03908580 Phase 4 COMPLETED

MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity

Started: 9/6/2013

NCT02757404 Phase 4 COMPLETED

Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity

Started: 5/30/2016

NCT01256021 Phase 4 COMPLETED

The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy

Started: 8/1/2010

NCT01259557 Phase 4 COMPLETED

Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm

Started: 8/1/2010

Drug Candidates

MT10109L Dose 1 MT10109L Dose 2 MT10109L Dose 1 + Dose 2 MT10109 MT10109L Placebo MT921 CORETOX® BOTOX® MBA-P01 (Botulinum toxin A)
Activity Status: Stale
Last Trial Started: 2/7/2022
Last Trial Ended: 5/30/2023
Trials (12 months): 0
Completed Trials: 42
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.